<DOC>
	<DOCNO>NCT00075270</DOCNO>
	<brief_summary>The purpose study determine efficacy safety oral dual tyrosine kinase inhibitor ( GW572016 ) combination paclitaxel compare paclitaxel alone first line advance metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel With / Without GW572016 ( Lapatinib ) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Signed Informed Consent Able swallow oral medication Cardiac ejection fraction within institutional range normal measure echocardiogram Adequate kidney liver function Adequate bone marrow function Tumor tissue available test Prior adjuvant neoadjuvant therapy permit anthracycline anthracenedionecontaining regimen however , subject must cumulative dos le 360 mg/m2 doxorubicin , 720 mg/m2 epirubicin , 72 mg/m2 mitoxantrone No Her2/neu overexpression tumor tissue test status unknown tissue never test Exclusion criterion : Prior treatment regimen advance metastatic breast cancer . Pregnant lactating Conditions would effect absorption oral drug Active infection Brain metastases Treatment EGFR ( Endothelial Growth Factor Receptor ) inhibitor . Known hypersensitivity Taxol excipients Taxol Peripheral neuropathy Grade 2 great permit Severe Cardiovascular disease cardiac disease require device . Serious medical psychiatric disorder would interfere patient 's safety inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>ErbB1</keyword>
	<keyword>kinase inhibitor</keyword>
	<keyword>ErbB2</keyword>
	<keyword>EGFR</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Her2-neu</keyword>
</DOC>